AlphAIAlphAI — Financial news for AI agents
247wallst.com$HIMS

Hims & Hers Drops 12% After Q3 Earnings Miss

Hims & Hers stock fell 12% after missing Q3 2026 earnings estimates, despite a recent partnership with Eli Lilly. The company's stock dropped from $22.11 to $19.44. Eli Lilly's shares rose 0.64%, and Amazon, a supplier, gained 1.72%.

Original reporting
247wallst.com
Published Nov 10, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 4:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Hims & Hers Drops 12% After Q3 Earnings Miss — source image
Source · 247wallst.com
Decision brief

The 30-second read

$HIMSBearishHigh
01

Why it matters

The earnings miss triggered a 12% drop, outweighing any positive sentiment from the Eli Lilly partnership.

02

Market read

The stock's sharp decline presents a short‑term trading opportunity.

03

What to watch

Potential upside from upcoming product launches not reflected in the earnings.

Relevance 7/10Novelty 8/10Timing: intraday today

Background

Hims & Hers is a telehealth company focused on sexual health and wellness products.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Hims & Hers reported a Q3 earnings miss, causing the stock to drop 12% intraday.

Expected impact

likely further downside as investors reassess guidance

Evidence & confidence

The earnings shortfall was the primary catalyst for the sharp price decline.

Market effects

Sector

Telehealth sector may face broader scrutiny after the miss.

Regional

U.S. market participants may adjust exposure to consumer health stocks.

Global

Limited to U.S. listed telehealth companies.

Counterpoint

What could challenge this read

The partnership with Eli Lilly could provide a longer‑term upside despite the miss.

Key entities

  • Company
    Hims & Hers Health Inc.

    Subject of the earnings miss.

Read at source← All news

StoryHims & Hers Cuts 2026 Profit Outlook Despite Strong Revenue Growth

Also covered by

5 outlets

Related articles

$HIMSMed

HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.

finance.yahoo.com
$HIMSHighAI 8/10

Hims & Hers Stock Falls 15% on Weak Q4 Revenue Outlook

Hims & Hers Health (HIMS) shares dropped 15% after the company issued Q4 revenue guidance below expectations, forecasting $875M–$895M vs. analysts' $955.1M estimate. Q3 revenue grew 49% to $890.4M but gross margin declined to 57% from 74%. The company also faces regulatory challenges over weight-loss medications and data privacy.

grafa.com
$HIMSHighAI 8/10

Hims & Hers cuts 2026 earnings outlook despite 49% revenue growth

Hims & Hers Health (HIMS) reported 49% revenue growth in Q3, but lowered its 2026 adjusted EBITDA forecast to $257M-$277M. Revenue guidance was tightened to $3.13B-$3.15B, with Q4 sales expected at $875M-$895M. International revenue surged 321%, while gross margin contracted to 57% from 74%. The company reported a net loss of $33M, with adjusted EBITDA margin falling to 9% from 13%.

finance.yahoo.com